Skip to main content
OpenTrials
Completed

NCT Number: NCT03049176

The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)

This is a prospective, non-randomized, open-label study to look at the uptake, adherence to, and impact of pre-exposure prophylaxis (PrEP), antiretroviral therapy (ART), semen washing, and vaginal insemination to prevent HIV among HIV-discordant couples attempting conception in Zimbabwe.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The reproductive needs of HIV-discordant couples who desire pregnancy represent an urgent public health problem that has been neglected in HIV prevention research. In Zimbabwe , and across sub-Saharan Africa, the vast majority of HIV-infected individuals are adults of reproductive age. Pregnancy and the desire for children are common among HIV-infected individuals, and HIV-discordant couples face a difficult choice between attempting pregnancy and risking HIV transmission to their partners. Recent surveys have found that 30-50% of HIV-infected individuals in sub-Saharan Africa are involved in stable, HIV-discordant relationships, and HIV transmission within married, cohabitating HIV-discordant couples accounts for 44-60% of new HIV infections in some regions of sub-Saharan Africa. While knowledge of HIV discordance can lead to increased condom use, many discordant couples have unprotected intercourse often motivated by the desire to conceive. Currently, HIV discordant couples who attempt to conceive place themselves at considerable risk of transmission. This research study aims to help promote couples' rights to conceive while at the same time decreasing the risk of HIV transmission.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For all couples:

  • Couple expresses a desire to conceive
  • Sexually active (defined as having vaginal sex with one another at least 6 times in the past 3 months
  • Willing to enter the study as a couple and intending to remain as a couple and have a sexual relationship for the next 12 months
  • Willing to use at least one safer conception strategy
  • For men, age ≥18 years. For women, age 18 - 35 years;
  • Able and willing to provide written informed consent

For HIV-uninfected members of the couple

  • HIV-negative based on parallel negative HIV rapid tests, both at study screening and enrollment visit
  • Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ≥60 mL/min

For HIV-infected members of the couple

  • HIV-positive based on parallel positive HIV rapid tests, based on national algorithm
  • No current AIDS-defining illness

Exclusion criteria

  • Amenorrheic
  • Currently pregnant
  • Active and serious infections, including active tuberculosis infection; active clinically significant medical problems including cardiac disease, pulmonary disease, and previously diagnosed malignancy expected to require further treatment.
  • History of infertility defined as a year or more of regular unprotected intercourse with current partner without pregnancy, or otherwise medically diagnosed infertility
  • Currently on any concomitant medication that requires the participant to avoid use of PrEP

Treatment and study plan

PrEP (Truvada)

Drug

oral, daily Truvada for HIV-negative participants

Other names: emtricitabine/tenofovir disoproxil fumarate

Antiretrovirals

Drug

oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant

Other names: ART

Semen washing

Procedure

collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination

Artificial vaginal insemination

Procedure

collection of semen from an HIV-negative man, followed by intravaginal insemination

Primary outcomes

  1. Uptake of safer conception strategies

    Time frame: 12 months

    proportion of couples choosing the strategy

  2. Acceptability of safer conception strategies

    Time frame: 12 months

    proportion of couples remaining on strategy; reports of satisfaction

  3. Adherence to safer conception strategies

    Time frame: 12 months

    proportion of couples with high adherence to strategy

Secondary outcomes

  1. Effectiveness of safer conception strategies on HIV prevention

    Time frame: 12 months

    incidence of HIV

  2. Effectiveness of safer conception strategies on achieving pregnancy

    Time frame: 12 months

    incidence of pregnancy

  3. costs of providing safer conception services

    Time frame: 12 months

    costs

  4. cost-effectiveness of safer conception strategies

    Time frame: 12 months

    model the cost effectiveness of various combinations of safer conception strategies

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Gilead Sciences
  • National Institute of Mental Health (NIMH)
  • UZ-UCSF Collaborative Research Programme

Registry information

Official study title

The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples

Acronym: SAFER

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Feb 9, 2017
Registry last updated
Sep 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.